Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Slow recruitement
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fonds de la Recherche en Santé du Québec | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Rapid tests are increasingly used in medical practice, notably to screen for HIV. Their use has been associated with a faster linkage to care and lower rates of loss to follow up. Rapid tests are also well accepted by patients and clinicians.
No rapid test is currently approved in Canada for screening of hepatitis C. Hepatitis C diagnosis is done through based on blood testing and the screening algorithm may require up to 3 visits to clarify the hepatitis C status.
The Oraquick HCV test is a rapid test done on blood or saliva that can replace the first step of the regular screening algorithm. With this test the initial screening and the confirmation test can be done in one visit.
The primary endpoint of this pilot-project is to evaluate clinical characteristics of Oracquick HCV (sensitivity, specificity, positive and negative predictive values) and to compare them to those of the standard screening algorithm in a population of active or ex-users of injected drugs. The project also intend to evaluate if the rapid test can reduce the rates of loss to follow up and increase the linkage to hepatitis C specialized care. This last endpoint will be evaluated through phone call follow up 6 months after the screening.
One hundred and fifty patients will be included. Half will be tested with the standard algorithm and the Oraquick HCV test (group A) and half will be tested only with the standard algorithm.
Results of group A will be used to determine the clinical characteristics of Oraquick HCV. Results of groups A and B will be used to evaluate rates of loss to follow up, costs avoided by the use of the rapid test and linkage to care of infected patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Experimental | Patients will be tests with both the standard algorithm and the Oraquick HCV Rapid Antibody Test |
|
| Group B | Active Comparator | Patients will be tested only with the standard algorithm |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oraquick HCV Rapid Antibody Test | Device |
| ||
| Standard algorithm |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients for whom Oraquick HCV Antibody Test accurately diagnosed anti-HCV status | Oraquick HCV Antibody test will be compared to a composite goldstandard:
| Patients will be followed for an expected average of 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Loss to follow up | Proportion of patients not completing the screening procedures | 3 months |
| Linkage to care | Proportion of infected patients initiating a follow up with an hepatitis C specialized provider |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Valérie Martel-Laferrière, MD | Centre hospitalier de l'Université de Montréal (CHUM) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier de l'Université de Montréal | Montreal | Quebec | H2L 2W5 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 6 months |
| Avoided costs | Costs that could have been avoided by the use of the rapid test. | 6 months |
| Satisfaction | Patients and provider satisfaction about the test | 15 minutes |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided